國立高雄大學圖資館 |

語系: 繁體中文

說明(常見問題)

圖資館首頁

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Cancer drug delivery systems based o...

Matsumura, Yasuhiro.

Cancer drug delivery systems based on the tumor microenvironment

紀錄類型:	書目-電子資源 : Monograph/item
正題名/作者:	Cancer drug delivery systems based on the tumor microenvironmentedited by Yasuhiro Matsumura, David Tarin.
其他作者:	Matsumura, Yasuhiro.
出版者:	Tokyo :Springer Japan :2019.
面頁冊數:	xi, 325 p. :ill. (some col.), digital ;24 cm.
Contained By:	Springer eBooks
標題:	Pharmaceutical technology.
電子資源:	https://doi.org/10.1007/978-4-431-56880-3
ISBN:	9784431568803$q(electronic bk.)

Cancer drug delivery systems based on the tumor microenvironment
Cancer drug delivery systems based on the tumor microenvironment[electronic resource] /edited by Yasuhiro Matsumura, David Tarin. - Tokyo :Springer Japan :2019. - xi, 325 p. :ill. (some col.), digital ;24 cm.

Preface -- Part I Cancer pathophysiology -- 1. The Cancer Stroma and its relevance to tumor survival -- 2. Cancer and blood coagulation -- 3. Tumor Blood Vessels as targets for cancer therapy -- 4. Stromal barriers within the tumor microenvironment and obstacles to nanomedicine -- Part II Antibody drug conjugates (ADC) -- 1. Recent progress in linker technology for antibody-drug conjugates: Methods for connection and release -- 2. Preclinical studies of ADC therapy for solid tumors -- 3. ADCs on the market and in clinical development -- Part III Hybrid techniques of active and passive targeting -- 1. Micelles conjugated with a pilot molecule -- 2. Liposomes conjugated with a pilot molecule -- 3. Multifunctional Envelope-type Nano Devices (MEND) for cancer therapy -- Part IV Cancer stromal targeting (CAST) therapy and diagnosis -- 1. Principle of CAST -- 2. CAST therapy -- 3. CAST diagnosis -- Part V The Current Status of Cancer Drug Delivery Systems and Future Directions -- Index.

This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.

ISBN: 9784431568803$q(electronic bk.)

Standard No.: 10.1007/978-4-431-56880-3doiSubjects--Topical Terms:

237657
Pharmaceutical technology.

LC Class. No.: RS380 / .C35 2019

Dewey Class. No.: 615.19

Cancer drug delivery systems based on the tumor microenvironment
LDR:03648nmm a2200325 a 4500 001 569177
003 DE-He213
005 20200107124203.0
006 m d
007 cr nn 008maaau
008 200723s2019 ja s 0 eng d
020 $a 9784431568803$q(electronic bk.)
020 $a 9784431568780$q(paper)
024 7 $a 10.1007/978-4-431-56880-3 $2 doi
035 $a 978-4-431-56880-3
040 $a GP $c GP
041 0 $a eng
050 4 $a RS380 $b .C35 2019
072 7 $a TDCW $2 bicssc
072 7 $a MED072000 $2 bisacsh
072 7 $a TDC $2 thema
082 0 4 $a 615.19 $2 23
090 $a RS380 $b .C215 2019
245 0 0 $a Cancer drug delivery systems based on the tumor microenvironment $h [electronic resource] / $c edited by Yasuhiro Matsumura, David Tarin.
260 $a Tokyo : $b Springer Japan : $b Imprint: Springer, $c 2019.
300 $a xi, 325 p. : $b ill. (some col.), digital ; $c 24 cm.
505 0 $a Preface -- Part I Cancer pathophysiology -- 1. The Cancer Stroma and its relevance to tumor survival -- 2. Cancer and blood coagulation -- 3. Tumor Blood Vessels as targets for cancer therapy -- 4. Stromal barriers within the tumor microenvironment and obstacles to nanomedicine -- Part II Antibody drug conjugates (ADC) -- 1. Recent progress in linker technology for antibody-drug conjugates: Methods for connection and release -- 2. Preclinical studies of ADC therapy for solid tumors -- 3. ADCs on the market and in clinical development -- Part III Hybrid techniques of active and passive targeting -- 1. Micelles conjugated with a pilot molecule -- 2. Liposomes conjugated with a pilot molecule -- 3. Multifunctional Envelope-type Nano Devices (MEND) for cancer therapy -- Part IV Cancer stromal targeting (CAST) therapy and diagnosis -- 1. Principle of CAST -- 2. CAST therapy -- 3. CAST diagnosis -- Part V The Current Status of Cancer Drug Delivery Systems and Future Directions -- Index.
520 $a This book proposes the importance of new systems of drug design and delivery based on cancer pathophysiology in addition to cancer molecular and cellular biology. The current studies based on molecular and cellular biology while ignoring pathophysiology and pharmacology may be leading the development of antitumor drugs in the wrong direction and wasting a lot of money. Although there have been numerous reports of genetic and phenotypic changes in tumors, a large body of pathological and clinical evidence supports the conclusion that there are no pivotal changes in tumor cells that distinguish them consistently and reliably from normal dividing cells. Unlike using antibiotics against bacterial infection, therefore, anticancer agents (ACAs) need to be delivered selectively to tumor tissues and should be kept there long enough to reproduce the concentrations they reach in the Petri dish, which is a closed space where the cytocidal effects of any anticancer agents (ACAs) including molecular targeting agents are very strong. In the body, however, administered ACAs are cleared with the passage of time. Furthermore, most human cancers possess abundant stroma that hinders the penetration of drugs into the tumor microenvironment. Therefore, to overcome these difficulties, novel drug delivery systems have been designed, such as nanoparticles and ACA conjugated antibodies to stromal components and to cancer cell surface antigens. These advances are described in this book after the first section, which describes core features of the pathophysiology of the cancer microenvironment, on which these new developments are based.
650 0 $a Pharmaceutical technology. $3 237657
650 0 $a Cancer $x Research. $3 341951
650 0 $a Nanoscience. $3 220425
650 0 $a Nanostructures. $3 215130
650 1 4 $a Pharmaceutical Sciences/Technology. $3 338426
650 2 4 $a Cancer Research. $3 273660
650 2 4 $a Nanoscale Science and Technology. $3 489389
700 1 $a Matsumura, Yasuhiro. $3 855063
700 1 $a Tarin, David. $3 855064
710 2 $a SpringerLink (Online service) $3 273601
773 0 $t Springer eBooks
856 4 0 $u https://doi.org/10.1007/978-4-431-56880-3
950 $a Biomedical and Life Sciences (Springer-11642)